|View printer-friendly version|
Varlitinib is a highly potent pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. At
In a second poster, new data will be presented from a Phase 1b study of varlitinib to determine the maximum tolerated dose in advanced solid tumours as combination therapy with paclitaxel. The recommended dose of varlitinib in combination with paclitaxel was found to be 300mg BID. Varlitinib showed efficacy in HER2+ metastatic breast cancer patients with some patients experiencing relatively long durations of response. The study was conducted by Dr.
Details of the presentations:
Poster Number: 326a
Abstract Number: TPS4143
Abstract Title: TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
Session Title: Gastrointestinal (Non-colorectal) Cancer
Location: Hall A
Poster Number: 414
Abstract Number: 2588
Abstract Title: Dose finding study of varlitinib ± trastuzumab with carboplatin/paclitaxel in advanced solid tumors.
Session Title: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Date and time:
Location: Hall A
The abstracts are available online at asco.org at: http://abstracts.asco.org/
Media and IR contacts
Tel: +886 2 2758 3333
Tel: +65 6340 7287
|Robert H Uhl
Tel: +1 858 356 5932
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumor growth. Varlitinib is currently being studied in gastric, biliary tract, breast and colorectal cancers. Varlitinib has been granted orphan drug designation in